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The assessment of new drugs and treatments is extremely important to the clinician in the seslection of best therapy. Knowledge of this type 
can be obtained only from clinical trials, which can pros
vide reliable evidence for effective use. Decisions about 
some treatments are difficult, and conflicting evidence 
from studies with weak design and poorlysreported 
methodological standards propagates the confusion.1 
Randomized controlled trials (RCTs) conducted within 
clinical trials are the gold standard by which health care 
professionals and others make decisions about treats
ment effectiveness.2 RCTs produce the best evidence for 
medical decisionsmaking by providing information on 
the superiority, equivalence or inferiority of one clinis
cal intervention compared with another. But RCTs, like 
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BACKGROUnD: no study has been conducted on the scientific quality of randomized controlled trials (rcts) in 
the cancer field. our objective was to determine whether adherence to the consolidated Standards for reporting 
trials (conSort) statement is associated with scientific properties of rct reports from two leading cancer jour-
nals.
METHODS: We conducted an observational study of rcts published between 2002 and 2004 in two leading 
cancer journals that did not endorse the conSort statement during that period. We determined the adherence 
rates with confidence intervals of 33 rcts according to the 19 methodological items of the conSort statement. 
each rct was blindly assessed by three independent evaluators; then the evaluators examined all judgments 
sequentially and obtained a consensus regarding each methodological item of the conSort statement. 
RESULTS: the average adherence of these 33 rcts to the 19 methodological items of the conSort statement 
was 79.3% (95% ci, 75.3-83.4%). most descriptors from the checklist were determined to be methodologically 
adequate except sequence generation (56.1%; 95% ci, 40.9-71.3%), allocation concealment (27.3%; 95% ci, 
13.2-41.4%), implementation (7.6%; 95% ci, 0.0-15.4%), blinding (30.3%; 95% ci, 14.4-46.3%) and sample 
size (74.2%; 95% ci, 59.5-89.0%). of all conSort checklist items, randomization implementation was the 
most often omitted. 
COnCLUSIOn: Some key methodological items of the conSort statement seem poorly addressed in rcts 
from these leading cancer journals. thus researchers should be urged to conform to the conSort statement 
when reporting on rcts, and the poorly addressed items of the conSort statement should be reevaluated for 
rcts already reported. 
other forms of research, suffer from bias,3,4 which can 
be assessed by checklists based on the methodological 
principles for reducing or eliminating bias. 
In 1995, as many as 25 scales and 9 checklists were in 
use.5 The Consolidated Standards for Reporting Trials 
(CONSORT) statement6 is the most comprehensive 
and the most widely used of those currently available. In 
the mids1990s, two independent initiatives to improve 
the quality of RCT reporting led to the publication of 
the CONSORT statement, a checklist of 30 evaluation 
criteria developed by an international group of clinical 
trialists, statisticians, epidemiologists, and biomedical 
editors.7 The CONSORT statement has been supports
ed by numerous journals and editorial groups including 
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(ICMJE), the Council of Science Editors (CSE), and the 
World Association of Medical Editors (WAME). The 
statement is listed as a criterion for acceptance of articles 
in many important journals. Nowadays, in their instrucs
tions to authors, more than 200 medical journals (such 
as Lancet, NEJM) have declared use of the CONSORT 
statement an essential reporting requirement (www.cons
sortsstatement.org). The checklist has experienced some 
changes in the last decade. The last CONSORT states
ment, published in 2001, included 22 items.8 Because 
the CONSORT statement has been shown to improve 
the scientific quality of RCT reporting, the statement 
has enjoyed widespread use in various medical fields 
such as surgery, anesthesia, and psychiatry.11s14 
Unfortunately, deficiencies persist in some reports 
of RCTs, even though the publishing journals have ens
dorsed CONSORT.15 However, these deficiencies may 
not arise from the methodological insufficiency of the 
RCT. Indeed, some CONSORT checklist items may be 
inappropriate in certain medical fields, and the checklist 
may not cover some properties of certain RCTs.16 The 
creators of the checklist are aware of these inadequas
cies too, so they have made several efforts to update the 
checklist.17
Cancer is one of the leading causes of death in the 
world today. To date, no study has been conducted on the 
scientific quality of RCTs in the cancer field. Therefore, 
we aimed to examine RCTs from two leading cancer 
journals according to the 19 methodological items in the 
CONSORT statement.
METHODS 
The CONSORT statement of 2001 (Figure 1) consists 
of 22 items.6 We assessed the selected RCTs from two 
leading cancer journals according to only 19 methods
ological items. The last three items on the CONSORT 
list were excluded from this assessment because they fall 
out of the limits of methodological evaluation. 
Data are expressed as mean and 95% confidence 
interval or number (percentages), or mean±SD. 
Normality distribution of the CONSORT item scores 
was tested using the one sample KolmogorovsSmirnov 
test. Differences in the CONSORT item scores between 
journals were compared using the MannsWhitney U 
test. A Psvalue <0.05 was considered statistically signifis
cant.
We selected two cancer journals ( Journal of National 
Cancer Institute, JNCI and Clinical Cancer Research, 
CCR). The impact factor of JNCI was 13.84 and of 
CCR was 6.51 according to the ISI Web of Science for 
2002. During the time covered by our study, neither 
journal required application of the CONSORT states
ment in their instructions to authors. Both journals 
were searched via Medline, from 1 January 2002 to 31 
December 2004. Selection of RCTs was made based on 
the appearance of the words “randomized” and “clinical 
trial” or “controlled trial”. A total of 206 RCTs matched 
this search criteria, 46 from NJCI and 160 from CCR. 
Studies selected for assessment included Phase II or lats
er, prospective, completed, comparisons with treatment 
groups (except descriptive or preventive) and original res
search (except brief reports). A final group of 33 RCTs 
were found as meeting these criteria, 17 from JNCI and 
16 from CCR. 
Each article was blindly assessed by three indepens
dent evaluators (NS, OU, MS). The result of each item 
was assessed by yes (1 point) or no (0 point), and some 
items were assessed as not applicable due to the features 
of studies. Moreover, items (items 4, 9, 10, 13, 17) ins
cluding more than one conceptual properties were ass
sessed by 0.5 point if the RCT did not include all of the 
conceptual properties. After all the articles were assessed 
according to the CONSORT guidelines, independent 
evaluators examined all judgments in order. Consensus 
was obtained among the evaluators, taking the decision 
of those that were most clearly argued when the differs
ent judgments were obtained for a particular study/
item. This permitted us to assign a single judgment to 
each item in each article.
RESULTS
We selected a total of 33 RCTs in the two leading cancer 
journals. Figure 2 shows a flow chart for the selection 
of studies considered for inclusion. The distribution of 
each methodological item of the CONSORT statement 
in the two journals is shown in Table 1. Some meths
odological items from the checklist, including “sample 
size”, “randomization” (sequence generation, allocation 
concealment, implementation) and “blinding” were 
poorly described, while we assessed most other items 
as adequately reported. The average mean for a positive 
“yes” or deficient status for 19 CONSORT descriptors 
was 15.0±2.2 (13.8±1.8 for CCR, and 16.2±1.9 for 
JNCI). Even though the purpose of the study did not 
include comparing the level of scientific quality level of 
RCTs in both journals, we found that the quality level of 
published RCTs in JNCI was significantly higher than 
in CCR (P<0.001). This difference arises from higher 
scores by studies in JNCI on randomization (sequence 
generation, allocation concealment) and blinding. Of all 
methodological items of the CONSORT statement, 
randomization implementation was the most often 
omitted in the selected studies. 
Table 2 shows the adherence of the selected RCTs 
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Paper	section	and	topic	 Item Description
TITLE	&	ABSTRACT	 1
How participants were allocated to interventions (e.g., “random allocation”, “randomized”, or “randomly 
assigned”).
INTRODUCTION	
   Background
2 Scientific background and explanation of rationale.
METHODS 
   participants 
3 eligibility criteria for participants and the settings and locations where the data were collected. 
   interventions 4 precise details of the interventions intended for each group and how and when they were actually administered.
   Objectives 5 Specific objectives and hypotheses
   Outcomes 6 Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).
   Sample size 7 How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.
   randomization b  
   Sequence generation 8
method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, 
stratification). 
   randomization b 
   allocation concealment 9
method used to implement the random allocation sequence (e.g., numbered containers or central telephone), 
clarifying whether the sequence was concealed until interventions were assigned. 
   randomization b 
   implementation 10
Who generated the allocation sequence, who enrolled participants, and who assigned participants to their 
groups. 
   Blinding (masking) 11 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. When relevant, how the success of blinding was evaluated. 
   Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); methods for additional analyses, such as subgroup analyses and adjusted analyses. 
RESULTS	
   participant flow
13
Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group 
report the numbers of participants randomly assigned, receiving intended treatment, completing the study 
protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together 
with reasons. 
   recruitment 14 Dates defining the periods of recruitment and followbup. 
   Baseline data 15 Baseline demographic and clinical characteristics of each group. 
   numbers analyzed 16 number of participants (denominator) in each group included in each analysis and whether the analysis was by “intentionbtobtreat” . State the results in absolute numbers when feasible (e.g., 10/20, not 50%). 
   Outcomes and   
   estimation 17
For each primary and secondary outcome, a summary of results for each group, and the estimated effect size 
and its precision (e.g., 95% confidence interval). 
   ancillary analyses 18 address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those prebspecified and those exploratory. 
   adverse events 19 all important adverse events or side effects in each intervention group. 
DISCUSSION	
   interpretation 
20 interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes. 
   Generalizability 21 Generalizability (external validity) of the trial findings. 
   Overall evidence 22 General interpretation of the results in the context of current evidence. 
to the CONSORT statement. In two articles of JNCI, 
item 19, adverse effect was deemed not applicable, so the 
assessment of these RCTs was made using only 18 items. 
The range of omitted methodological items (items 8s11) 
was found to be 11.8% to 76.5% in JNCI and 3.1% to 
34.4% in CCR. Mean average scores for these items 
ranged from 7.6% to 56.1%. The average adherence of 
the selected RCTs to the CONSORT statement was 
79.3% (95% CI, 75.3s83.4%).
DISCUSSIOn
Significant methodological features of RCTs published 
Figure	1.	COnSOrT statement (2001).6
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Table	1.	Distribution of 19 methodological items of the COnSOrT statement.
Yes No Deficient Not	applicable
1. randomization 27 (81.8) 0 (0.0) 6 (18.2) 0 (0.0)
2. Background 33 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
3. participants 33 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
4. interventions 33 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
5. Objectives 30 (90.9) 0 (0.0) 3 (9.1) 0 (0.0)
6. Outcomes 32 (97.0) 0 (0.0) 1 (3.0) 0 (0.0)
7. Sample size 23 (69.7) 7 (21.2) 3 (9.1) 0 (0.0)
8. Sequence generation 14 (42.4) 10 (30.3) 9 (27.3) 0 (0.0)
9. allocation concealment 6 (18.2) 21 (63.6) 6 (18.2) 0 (0.0)
10. implementation 1 (3.0) 29 (87.9) 3 (9.1) 0 (0.0)
11. Blinding (masking) 9 (27.3) 22 (66.7) 2 (6.0) 0 (0.0)
12. Statistical methods 32 (97.0) 0 (0.0) 1 (3.0) 0 (0.0)
13. participant flow 24 (72.7) 0 (0.0) 9 (27.3) 0 (0.0)
14. recruitment 24 (72.7) 2 (6.1) 7 (21.2) 0 (0.0)
15. Baseline data 33 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
16. numbers analyzed 33 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
17. Outcomes and estimation 26 (78.8) 0 (0.0) 7 (21.2) 0 (0.0)
18. ancillary analyses 25 (75.8) 2 (6.1) 6 (18.1) 0 (0.0)
19. adverse events 25 (75.8) 3 (9.1) 3 (9.1) 2 (6.0)
Values are expressed number (percentage)
all issues of nJCi and CCr
between 2002 and 2004 were 
searched
206 articles matched the criteria
   46 from nJCi
   160 from CCr
33 rCTs included in analysis
   17 from nJCi
   16 from CCr
Searching of rCTs was done by meDline using the 
words “randomized”, “clinical trial”,  “controlled trial”
phasebii or later, prospective, completed, comparing with 
treatment groups (except descriptive or preventive) and 
original researches (except brief report) were included
rCTs were assessed blindly by 3 
independent evaluators
Figure	2.	Flow diagram showing selection of reports for inclusion in study.
in leading medical journals had been reported as shows
ing low accordance with necessary methodological feas
tures even prior to CONSORT. Some key methods
ological factors, including explanation of randomization 
method, statistical power of the trial and eligibility cris
teria for participants were reported as falling as low as 
19%, 12%, and 37%, respectively.18 Although scientific 
quality has increased nowadays, adherence to all items of 
the checklist by all RCT reports is not required by either 
CONSORTspromoting or nonsCONSORTspromots
ing journals.9 However, this study shows the possibility 
for improvement in the quality of RCT reports by the 
use of the checklist. For example, effective randomizas
tion concealment was reported in 57% of RCTs res
ported in CONSORTspromoting journals, but in only 
35% of RCT reports from nonsCONSORTspromots
ing journals. On the other hand, the appropriateness of 
baseline data (item 15) was assessed at more than 90% 
for both journal types.9 Randomization allocation was 
found effective in 76% of RCT reports in CONSORTs
promoting journals, but in only 45% of RCT reports 
in nonsCONSORTspromoting journals.9 Data analyst 
blinding status in RCTs reported in CONSORTspros
moting journals was 8%, but it was 0% in RCTs in nons
CONSORTspromoting journals.9 These differences 
may arise from the insufficient scientific quality of the 
RCTs or due to the properties of RCTs conducted in 
specific medical fields, which make it inappropriate to 
apply all the items of the CONSORT statement.
There are several limitations to this study. This was 
an observational study based on MEDLINE searching 
in a 3syear period and included RCTs of two leading 
cancer journals only. Therefore, it may not be represens
tative of all cancer or leading cancer journals and the ins
clusion of their RCTs might change the appropriateness 
to the CONSORT. 
In our study, randomizationsimplementation was 
explained in only 7.6% of RCTs, receiving the lowest 
average score of all CONSORT items. Effective res
porting of this item in RCT, in obstetric anaesthesia 
had been reported as 10%, which was also considered 
low.12 Appropriateness of sample size calculation that 
study was 60%,12compared with 74.2% in our study. 
Randomizationssequence generation in RCTs from nons
CONSORT promoting journals was reported as 45%,9 
but was found to be 56.1% in our study. These items 
(sequence generation and sample size) are indisputable 
methodological characteristics of an RCT, so researchers 
should pay more attention to these items in their studies. 
In our study, the randomization allocation concealment 
was appropriately explained in only 27.3% of RCTs, a 
low score, which may be due to deficient description. 
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Table	2.	The COnSOrT items reported by the Journal of the national Cancer institute and Clinical Cancer research.
Criteria Average JNCI CCR	
1 randomization 90.9 (84.0b97.9) 94.1 (85.6b100) 87.5 (75.6b99.4)
2 Background 100 ( – ) 100 ( – ) 100 ( – )
3 participants 100 ( – ) 100 ( – ) 100 ( – )
4 interventions 100 ( – ) 100 ( – ) 100 ( – )
5 Objectives 95.5 (90.3b100.6) 100 ( – ) 90.6 (79.9b101.4)
6 Outcomes 98.5 (95.4b100) 97.1 (90.8b100) 100 ( – )
7 Sample size 74.2 (59.5b89.0) 85.3 (67.7b100) 62.5 (37.7b87.3)
8 Sequence generation 56.1 (40.9b71.3) 76.5 (55.9b97.0) 34.4 (15.6b53.1)
9 allocation concealment 27.3 (13.2b41.4) 44.1 (20.3b68.0) 9.4 (b1.4b20.3) 
10 implementation 7.6 (0.0b15.4) 11.8 (b2.7b26.2) 3.1 (b3.5b9.8)
11 Blinding (masking) 30.3 (14.4b46.3) 41.2 (15.1b67.3) 18.8 (0.0b37.9)
12 Statistical methods 98.5 (95.4b101.6) 100 ( – ) 96.9 (90.2b103.5)
13 participant flow 86.4 (78.4b94.4) 100 ( – ) 71.9 (58.2b85.5)
14 recruitment 83.3 (72.8b93.9) 100 ( – ) 65.6 (46.9b84.4)
15 Baseline data 100 ( – ) 100 ( – ) 100 ( – )
16 numbers analyzed 100 ( – ) 100 ( – ) 100 ( – )
17 Outcomes and estimation 89.4 (82.0b96.8) 100 ( – ) 78.1 (64.5b91.8)
18 ancillary analyses 84.9 (74.5b95.2) 97.1 (90.0b100.3) 71.9 (52.5b90.0)
19 adverse events 85.5 (73.7b97.3) 86.7 (67.2b106.1) 84.4 (68.3b100.4)
Total 79.3	(75.3	-83.4) 85.9	(81.3	–	90.5) 72.4	(67.3	–	77.5)
Values are expressed percentage and (%95 confidence interval)
Table	3.	Comparison of poor methodological items in leading COnSOrT promoting journals and leading nonbCOnSOrT promoting 
cancer journals.
Criteria
Leading	CONSORT	promoting	journalsa Present	study
Appropriateness	(%) Appropriateness	(%)
Sequencebgeneration 80.2 56.1
allocation concealment 48.2 27.3
implementation 55.3 7.6
Blinding 81.4 30.3
Sample size 82.6 74.2
a Study by mills et al.    
Moreover, one of the indisputable items of RCTs is 
blinding which we determine as correctly explained in 
only 30.3% of the reports in our study. However, in a 
study of ophthalmologic RCTs, blinding of the data anas
lysts only appeared in 4.5% of reports, whereas blinding 
of participants was reported in 68.4%.19 Hence, it can 
be concluded that blinding in some medical fields might 
be too hard or impossible for all study participants, ins
cluding subjects, interventionists, outcome evaluators, 
and data analysts. Although the blinding items, the first 
three items on the original CONSORT statement, were 
reduced to one item in the new checklist, the deficiens
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cies still continue. All other methodological items in the 
checklist reflect base characteristics of RCTs and most 
were adequately fulfilled in the RCTs of our study. The 
average appropriateness of RCTs from leading two 
cancer journals to the CONSORT statement (79.3%) 
may give an idea about scientific quality of cancer RCT 
reports in leading cancer journals, but one needs to be 
careful in interpretation due to the fact that the study 
included only two leading cancer journals. 
In the RCTs reported in Chinese medical journals, 
many methodological items of the CONSORT states
ment (sample size, allocationsconcealment and imples
mentation, blinding, dates defining the periods of res
cruitment, ancillary analyses, interpretation sources of 
potential bias or imprecision, and dangers associated 
with multiplicity of analyses and outcomes) had not 
been described,20 whereas in our study these criteria 
were highly reported, except for allocationsconceals
ment, implementation and blinding, rated as effective 
in 27.3%, 7.6% and 30.3% of studies, respectively. 
These differences in the quality of RCT reports likely 
arise due to the scientific qualities of journals.
In leading medical CONSORTspromoting jours
nals, the reporting of key methodological items (ses
quence generation, allocation concealment, implemens
tation and blinding) was assessed as poor despite revis
sion of the checklist,10 but in the present study, reports 
in leading nonsCONSORT promoting cancer journals 
were assessed as even lower (Table 3). The lower ads
herence to the key methodological items in reports in 
leading nonsCONSORT promoting cancer journals 
shows the possibility of significant improvement in the 
scientific quality of RCTs using the CONSORT states
ment, even in the leading medical journals.
In conclusion, RCTs which are conducted with scis
entific responsibility can fulfill basic methodological 
characteristics without use of the CONSORT states
ment, but the checklist improves the scientific quality 
of RCTs by assisting authors in the planning, prepars
ing and conducting of RCTs, and by guiding editors in 
the auditing of studies. Since we found the adherence 
to key methodological factors on the checklist poor 
in RCTs reported in many different medical journals, 
both CONSORTspromoting or nonsCONSORTs
promoting,1,4,9,10,12,19s21 researchers should be urged to 
conform to the CONSORT statement, with extra 
consideration given to those items found to have the 
lowest average scores.
1.	Thakur a, Wang eC, Chiu TT, Chen W, Ko Cy, 
Chang JT, et al. methodology standards associb
ated with quality reporting in clinical studies in 
pediatric surgery journals. J pediatr Surg. 2001; 
36:1160b1164.
2.	moher D, Jones a, lepage l, for the COnSOrT 
Group. use of the COnSOrT statement and quality 
of reports of randomized trials: a comparative beb
forebandbafter evaluation. Jama. 2001; 285:1992b
1995.
3.	Schulz KF, Chalmers i, Hayes rJ, altman DG. 
empirical evidence of bias. Dimensions of methb
odological quality associated with estimates of 
treatment effects in controlled trials. Jama. 1995; 
273:408b412. 
4.	 Huwilerbmuntener K, Juni p, Junker C, egger 
m. Quality of reporting of randomized trials as a 
measure of methodologic quality. Jama. 2002; 
287:2801b2804.
5.	moher D, Jadad ar, nichol G, penman m, Tugb
well p, Walsh S. assessing the quality of randomb
ized controlled trials: an annotated bibliography 
of scales and checklists, Control Clin Trials. 1995; 
16:62b73.
6.	COnSOrT Statement [Homepage on the interb
net]. Ottawa. [cited 2005 December 1]. available 
from: http://www.consortbstatement.org/Stateb
ment/revisedstatement.htm.
7.	Begg C, Cho m, eastwood S, Horton r, moher D, 
Olkin i, et al. improving the quality of reporting of 
randomized controlled trials. The COnSOrT stateb
ment. Jama. 1996; 276:637b639.
8.	moher D, Schulz KF, altman D. COnSOrT Group. 
The Consort statement: revised recommendab
tions for improving the quality of reports of paralb
lelbgroup randomized trials. ann intern med. 2001; 
134:657b662.
9.	Devereaux pJ, manns BJ, Ghali Wa, Quan H, 
Guyatt GH. The reporting of methodological facb
tors in randomized controlled trials and the assob
ciation with a journal policy to promote adherence 
to the Consolidated Standards of reporting Trials 
(COnSOrT) checklist. Control Clin Trials. 2002; 
23:380b388.
10.	 mills eJ, Wu p, Gagnier J, Devereaux pJ. 
The quality of randomized trial reporting in leadb
ing medical journals since the revised COnSOrT 
statement. Contemp Clin Trials. 2005; 26:480b487.
11.	Sauerland S, Davis Tr. The Consolidated Stanb
dards of reporting Trials (COnSOrT): better preb
sentation of surgical trials in the journal of hand 
surgery, J Hand Surg [Br]. 2004; 29: 621b624.
12.	Halpern SH, Darani r, Douglas mJ, Wight W, 
yee J. Compliance with the COnSOrT checklist in 
obstetric anaesthesia randomised controlled trib
als. int J Obstet anesth. 2004; 13:207 b214.
13.	 Grimes Da. The “COnSOrT” Guidelines for 
randomized Controlled Trials in Obstetrics & Gyb
necology. Obstet Gynecol. 2002; 100:631b632.
14.	 Khan a, Khan Sr, leventhal rm, Krishnan 
Krr, Gorman Jm. an application of the revised 
COnSOrT standards to FDa summary reports of 
recently approved antidepressants and antipsyb
chotics. Biol psychiatry. 2002; 52:62b67.
15.	 mills e, Wu p, Gagnier J, Heelsbansdell D, 
montori Vm. an analysis of general medical and 
specialist journals that endorse COnSOrT found 
that reporting was not enforced consistently. J 
Clin epidemiol. 2005; 58:662b667.
16.	 ioannidis Jp, evans SJ, Gotzsche pC, O’neill 
rT, altman DG, Schulz K, et al. Better reporting 
of harms in randomized trials: an extension of 
the COnSOrT statement. ann intern med. 2004; 
141:781b789.
17.	moher D, altman DG, Schulz KF, elbourne Dr. 
Opportunities and challenges for improving the 
quality of reporting clinical research: COnSOrT 
and beyond. Can med assoc J. 2004; 171: 349b351. 
18.	DerSimonian r, Charetta lJ, mcpeek B, mob
steller F. reporting on methods in clinical trials. J 
pediatr Surg. 2003; 38:556b559.
19.	 SanchezbThorin JC, Cortes mJ, montenegro 
m, Villate n. The quality of reporting of randomized 
clinical trials published in ophthalmology. Ophthalb
mology. 2001; 108:410b415. 
20.	peng X, Zhao y, liang X, Wu l, Cui S, Guo a, 
et al. assessing the quality of rCTs on the effect 
of hbelemene, one ingredient of a Chinese herb, 
against malignant tumors. Contemp Clin Trials. 
2006; 27:70b82.
21.	ellis C, Hall Jl, Khalil a, Hall JC. evoluation of 
methodological standards in surgical trials. anZ J 
Surg. 2005; 75:874b877. 
REfEREnCES
